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Abstract
X-linked myopathy with excessive autophagy (XMEA), caused by mutations of the VMA21 gene, is a strictly skeletal muscle disease. Extensive
studies in yeast establishedVMA21 as the master assembly chaperone ofV-ATPase, the complex multisubunit proton pump that acidifies organelles
and that is vital to all mammalian tissues.As such, skeletal muscle disease exclusivity in XMEA is highly surprising.We now show that the severest
VMA21mutation, c.164-6t>g, does result inXMEA-typical pathologywith autophagic vacuolar changes outside skeletalmuscle, namely in the heart.
However, even patients with this mutation do not exhibit clinical extramuscular disease, including cardiac disease, despite extreme skeletal muscle
wasting to the extent of ventilation dependence. Uncovering the unique skeletal muscle vulnerability to defective organellar acidification, and
resultant tissue-destructive excessive autophagy, will be informative to the understanding of muscle physiology. Alternatively, understanding
extramuscular resistance to VMA21 mutation might disclose heretofore unknown mammalian V-ATPase assembly chaperones other than VMA21.
© 2016 Elsevier B.V. All rights reserved.
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1. Introduction
We recently published a paper in Neuromuscular Disorders
titled: ‘No cardiomyopathy in X-linked myopathy with excessive
autophagy’ [1]. This was a comprehensive electrocardiography,
echocardiography and gadolinium-enhanced cardiac MRI study
in five members (ages 25–48 years) and cardiac autopsy in one
member of the original XMEA family [2]. No cardiac
abnormalities were present, including no autophagic vacuolation
under light or electron microscopy, which in skeletal muscle is
the defining feature of the disease. Absence of even subclinical
changes in the heart accentuated the puzzling aspect of XMEA
of apparent non-involvement of extra-skeletal muscle organs.
The disease is caused by mutations of a gene (VMA21) that
encodes the chief assembly chaperone of the V-ATPase proton
pump which is vital to all cells, yet to date pathology has been
reported only in skeletal myofibers, leukocytes and fibroblasts,
and clinical disease only in skeletal muscle [3].
All XMEA mutations are hypomorphic alleles that reduce
but do not eliminate VMA21 expression, most of them intronic
variants that act by reducing splicing efficiency [3]. Most XMEA
patients have a uniform clinical course as described in the
original family, namely insidious onset of limb girdle weakness
sometime in childhood with slow progression toward wasting
and ambulation loss after the fifth decade [2–5]. Few patients,
described more recently, have a much more severe course with
infantile or neonatal onset, sometimes with death in infancy
due to respiratory failure, minimal or no ambulation, and artificial
ventilation dependence. These patients have more severe
mutations, resulting in greater reductions in VMA21 expression
and V-ATPase activities, than those with classical XMEA [6,7].
Members of the worst affected family (Congenital Autophagic
Vacuolar Myopathy (CAVM); mutation c.164-6t>g) have a mild
cardiac hypertrophy on echocardiography, but additional testing
has not been performed, and whether their hearts exhibit
vacuolation is unknown [7].
2. Case report
In 1998 the case of a hypotonic male infant was reported,
with ventilation dependence, severe muscle weakness, and
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death by 27 months from respiratory insufficiency [8]. His
skeletal muscle pathology (electron-dense-debris-filled
vacuoles, deposition of complement membrane attack complex
on vacuoles and multiplication of the basal lamina) resembled
more closely the pathology of XMEA than that of Danon
disease, the vacuolar myopathy that most closely resembles
XMEA. Following identification of LAMP2 as the Danon
disease gene, he was shown to have no LAMP2 mutations and
normal LAMP2 protein in muscle, which exclude Danon
disease [8,9]. Upon his death permission was obtained for a
cardiac autopsy, and the heart showed slight hypertrophy and
‘scattered fibers with autophagic vacuoles on electron
microscopy’ [8]. Examination of the electron micrograph
provided with the original publication shows this cardiac
vacuolation to exactly resemble that of XMEA skeletal muscle.
To determine whether this old case was in fact an XMEA case,
we sequenced his DNA and found the same VMA21 c.164-6t>g
mutation as in our severest XMEA family mentioned above.
3. Discussion
The V-ATPase is a complex proton pump composed of
over 13 subunits. It is ubiquitous to all cells, using energy from
ATP to pump protons and acidify organelles, including
lysosomes, autolysosomes, the Golgi apparatus and others. It is
evolutionarily related to the P-ATPase, the last complex of the
mitochondrial electron transport chain, through which protons
flow in the reverse direction to generate, rather than consume,
ATP. Detailed work in yeast identified VMA21 as the master
assembly chaperone of the V-ATPase [10]. When VMA21 was
established as the XMEA gene, the question arose as to why
only skeletal muscle is affected. Even the heart was unaffected,
even with electron microscopic analysis [1].When patients with
the severest form of XMEA were described (mutation c.164-
6t>g associated with neonatal lethality or profound generalized
skeletal muscle wasting in surviving newborns), they too did
not have overt cardiac disease – cardiac tissue was unavailable
from these patients for microscopic analysis [7]. The present
study shows that this severe mutation (c.164-6t>g) does in fact
manifest the typical electron microscopic XMEA changes in
the heart, albeit subclinically. VMA21 therefore plays at least
some role in the heart, but the question remains as to why the
heart, and other extramuscular organs, are at most so minimally
affected with mutation of the assembly chaperone of the proton
pump vital to all tissues.
The present pathogenetic model of XMEA is as follows:
Reduced V-ATPase raises lysosomal pH, which impairs the
final degradative stage of autophagy. This failure upregulates
autophagy, at least in part through mTOR signaling, and drives
proliferation of autolysosomes, which in turn are unable to
complete autophagy and merge together to form the large
debris-filled vacuoles that characterize the disease [3]. VMA21
mutations reduceV-ATPase activity by 75% in classical XMEA
and by 90% in the severest form of the disease (CAVM) (c.164-
6t>g), as determined by measurements in biopsied skeletal
muscle and lymphoblasts [3,7]. Possibly, extramuscular organs
tolerate this degree of reduction, but would succumb to deeper
diminution of V-ATPase activity. In fact there are no known
patients with complete loss-of-function mutations. Another
possibility is that XMEA mutations, most of which affect
splicing, do so to a lesser extent in extramuscular tissues
allowing higher levels of VMA21 expression. However, this
possibility is less favored, because extramuscular cells tested,
lymphoblasts, have even lower residual V-ATPase activity than
skeletal muscle from the same patients [3,7]. Finally, it is
possible that in mammalian tissues there are assembly
chaperones other than the one, VMA21, identified through
studies of yeast.
As mentioned, Danon disease is the closest myopathological
differential diagnosis to XMEA. One of the major clinical
differences between the two diseases is the early and severe
involvement of the heart in the former, generally requiring
transplantation. Multiple functions have been attributed to the
LAMP2 protein, some of which indirectly overlap the known
function of VMA21. LAMP2 is involved in intracellular
motility of lysosomes, maintenance of the lysosome acidic
environment, fusion of lysosomes with autophagosomes, and
maturation of autolysosomes [11]. It is likely that the shared
autophagic vacuolation between the two diseases stems at
least in part from their shared effects on lysosomal and
autolysosomal acidification. But why is the heart so majorly
affected in Danon disease and not XMEA? Both are X-linked
diseases affecting primarily males. Most Danon disease
mutations lead to complete loss of the protein’s function,
while all XMEA mutations, even the severest (CAVM), leave
residual activity. Possibly, complete loss of VMA21, if
compatible with life, would result in just as severe cardiac
pathology as occurs in Danon disease. On the other hand,
females with Danon disease, who usually have 50% preserved
LAMP2 function, usually have only cardiac disease (and no
neurological or skeletal muscle disease) [11], indicating that it
is not the complete loss of LAMP2 function alone that underlies
the cardiac disease in males. Likely, functions of LAMP2 other
than lysosomal acidification, such as chaperone-mediated
autophagy and endosomal cholesterol transport [11], contribute
to the cardiomyopathy.
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